First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
Abstract. Background:. IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in clinical. The aim of this study was t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2019-12-01
|
| Series: | Chinese Medical Journal |
| Online Access: | http://journals.lww.com/10.1097/CM9.0000000000000536 |
| _version_ | 1818351031418880000 |
|---|---|
| author | Ling-Yu Li Hong Wang Xiao Chen Wen-Qian Li Jiu-Wei Cui Li-Min Chen |
| author_facet | Ling-Yu Li Hong Wang Xiao Chen Wen-Qian Li Jiu-Wei Cui Li-Min Chen |
| author_sort | Ling-Yu Li |
| collection | DOAJ |
| description | Abstract. Background:. IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in clinical. The aim of this study was to evaluate the cost-effectiveness of atezolizumab plus chemotherapy in treatment of extensive SCLC as first line in China.
Methods:. A Markov model was established by extracting data from the IMpower 133 trial with untreated extensive SCLC patients. Utility values were obtained from published studies, and the costs were acquired from real world and literature. Additionally, sensitivity analyses based on a willingness-to-pay (WTP) threshold were performed to identify the uncertain parameters of Markov model.
Results:. Total costs of atezolizumab group were $48,129, while cost of chemotherapy alone was just $12,920 in placebo group. The quality-adjusted life-years (QALYs) in atezolizumab group was just 0.072 higher than that in placebo group (0.858 QALYs vs. 0.786 QALYs). The cost-effectiveness ratio between atezolizumab combination with chemotherapy and chemotherapy alone was $489,013/QALY in China. The net benefit of placebo group was significantly higher than atezolizumab group. One-way sensitivity analyses highlighted that utilities of the progression-free survival (PFS) and progression disease state in placebo group were the most influential parameter.
Conclusions:. Atezolizumab combination therapy was not more cost-effective than chemotherapy alone at a WTP threshold of $25,929/QALY in China. |
| first_indexed | 2024-12-13T18:31:16Z |
| format | Article |
| id | doaj.art-17696b80f9704de49269144fea636c6f |
| institution | Directory Open Access Journal |
| issn | 0366-6999 2542-5641 |
| language | English |
| last_indexed | 2024-12-13T18:31:16Z |
| publishDate | 2019-12-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Chinese Medical Journal |
| spelling | doaj.art-17696b80f9704de49269144fea636c6f2022-12-21T23:35:28ZengWolters KluwerChinese Medical Journal0366-69992542-56412019-12-01132232790279410.1097/CM9.0000000000000536201912050-00004First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from ChinaLing-Yu Li0Hong Wang1Xiao Chen2Wen-Qian Li3Jiu-Wei Cui4Li-Min Chen5The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, China.The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, China.The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, China.The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, China.The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, China.The Cancer Center of the First Hospital of Jilin University, Changchun, Jilin 130021, China.Abstract. Background:. IMpower 133 trial first confirmed the efficacy and safety of adding atezolizumab or placebo to first-line treatment with chemotherapy in patients with extensive-stage small-cell lung cancer (SCLC). While, overprice limited its broad use in clinical. The aim of this study was to evaluate the cost-effectiveness of atezolizumab plus chemotherapy in treatment of extensive SCLC as first line in China. Methods:. A Markov model was established by extracting data from the IMpower 133 trial with untreated extensive SCLC patients. Utility values were obtained from published studies, and the costs were acquired from real world and literature. Additionally, sensitivity analyses based on a willingness-to-pay (WTP) threshold were performed to identify the uncertain parameters of Markov model. Results:. Total costs of atezolizumab group were $48,129, while cost of chemotherapy alone was just $12,920 in placebo group. The quality-adjusted life-years (QALYs) in atezolizumab group was just 0.072 higher than that in placebo group (0.858 QALYs vs. 0.786 QALYs). The cost-effectiveness ratio between atezolizumab combination with chemotherapy and chemotherapy alone was $489,013/QALY in China. The net benefit of placebo group was significantly higher than atezolizumab group. One-way sensitivity analyses highlighted that utilities of the progression-free survival (PFS) and progression disease state in placebo group were the most influential parameter. Conclusions:. Atezolizumab combination therapy was not more cost-effective than chemotherapy alone at a WTP threshold of $25,929/QALY in China.http://journals.lww.com/10.1097/CM9.0000000000000536 |
| spellingShingle | Ling-Yu Li Hong Wang Xiao Chen Wen-Qian Li Jiu-Wei Cui Li-Min Chen First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China Chinese Medical Journal |
| title | First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China |
| title_full | First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China |
| title_fullStr | First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China |
| title_full_unstemmed | First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China |
| title_short | First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China |
| title_sort | first line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer a cost effectiveness analysis from china |
| url | http://journals.lww.com/10.1097/CM9.0000000000000536 |
| work_keys_str_mv | AT lingyuli firstlineatezolizumabpluschemotherapyintreatmentofextensivesmallcelllungcanceracosteffectivenessanalysisfromchina AT hongwang firstlineatezolizumabpluschemotherapyintreatmentofextensivesmallcelllungcanceracosteffectivenessanalysisfromchina AT xiaochen firstlineatezolizumabpluschemotherapyintreatmentofextensivesmallcelllungcanceracosteffectivenessanalysisfromchina AT wenqianli firstlineatezolizumabpluschemotherapyintreatmentofextensivesmallcelllungcanceracosteffectivenessanalysisfromchina AT jiuweicui firstlineatezolizumabpluschemotherapyintreatmentofextensivesmallcelllungcanceracosteffectivenessanalysisfromchina AT liminchen firstlineatezolizumabpluschemotherapyintreatmentofextensivesmallcelllungcanceracosteffectivenessanalysisfromchina |